Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review - Takeaways - MDSpire

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review

  • By

  • Peng Tang

  • Weixing Liu

  • Yating Xu

  • You Long

  • Yixiao Li

  • Jiaxin Li

  • Mingheng Liao

  • Xin Wang

  • Jin Zhou

  • Yong Zeng

  • July 14, 2026

Share

  • 1

    Ectopic hepatocellular carcinoma (EHCC) is a rare malignancy occurring outside the liver without a detectable intrahepatic primary tumor.

  • 2

    A patient with unresectable, multifocal EHCC was treated by a multidisciplinary team using a multimodal regimen including lenvatinib and camrelizumab.

  • 3

    Comprehensive genomic analysis revealed significant upregulation of the interferon response pathway, potentially critical for EHCC pathogenesis.

  • 4

    The patient achieved a progression-free survival of 27 months and an overall survival of 30 months with the combination therapy.

  • 5

    A systematic review of 55 EHCC cases provided insights into the disease's demographic, clinical, management, and prognostic characteristics.

Original Source(s)

Related Content